MAPT and myotonic dystrophy type 1: Indeed, one major limitation of this study is lack of post-mortem data to confirm biomarker sensitivity to DM1 Tau pathology, and to rule out other comorbidities, like AD, which may be contributing to both the observed cognitive impairment and abnormal Tau and/or amyloid biomarkers.